CMOs Ratchet up use of Single-Use Devices to Improve Performance - Single-use systems continue to gain traction among biomanufacturers, especially CMOs. - BioPharm International

ADVERTISEMENT

CMOs Ratchet up use of Single-Use Devices to Improve Performance
Single-use systems continue to gain traction among biomanufacturers, especially CMOs.


BioPharm International
Volume 24, Issue 11, pp. 27-30

SUMMARY

There are many recognized benefits from the use of disposables, many of which can shorten lead-time to get a facility or campaign up and running. CMOs can be the first to reap these advantages, but all biomanufacturers have seen benefits. The top five reasons most commonly cited by all respondents as "most critical" include:

1. Reduce capital investment in facility and equipment (21% for 2011, up from 14.4% in 2009)

2. Eliminate cleaning requirements (12.6%)

3. Faster campaign turnaround (11.2%, up from 6.9% in 2009)

4. Decrease risk of product cross-contamination (8.4%)

5. Reduce time to get facility up and running (6.3%).

It is clear that single-use devices continue to gain acceptance in the industry, and that their benefits are being increasingly noticed. Over time, we expect biomanufacturers and CMOs to integrate disposables into most processes, especially as downstream single-use solutions and specific devices such as probes and sensors continue to evolve. In addition, as new regions such as China and India gain prominence and begin to produce biologics and biogenerics, the need for consistent quality will likely dictate the greater use of disposables, because they can often be implemented more efficiently and with fewer risks of quality problems (4). As new biomanufacturers enter the industry and new products enter the pipeline, the disposables option will become part of the decision process from the very start.

Eric S. Langer is president and managing partner at BioPlan Associates and a member of BioPharm International's editorial advisory board.
.

REFERENCES

1. BioPlan Associates, "8th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production: A Survey of Biotherapeutic Developers and Contract Manufacturing Organizations" (April 2011).

2. BioPlan Associates, "7th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production: Survey of Biotherapeutic Developers and Contract Manufacturing Organizations" (April 2010).

3. CMC Biologics, "CMC Biologics Adds 2,000 Liter Single-Use Bioreactor at its Copenhagen Manufacturing Facility," press release, (Copenhagen, Denmark, Sept. 1, 2011).

4. BioPlan's Top 1000 Global Biopharmaceutical Facilities Index, http://www.top1000bio.com/index.asp, accessed Aug. 20, 2011


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here